Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02331589 |
|
Recruitment Status :
Completed
First Posted : January 6, 2015
Results First Posted : February 10, 2015
Last Update Posted : February 10, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Background: Korea red ginseng (KRG) has anti-carcinogenic activity, anti-oxidant activity, and cancer related anti-fatigue.
Methods: Seventy five patients with non-alcoholic hepatitis were prospectively randomized to receive 3 weeks of KRG or placebo. Liver function test, pro-inflammatory cytokines, adiponectin, fatigue severity scale, and antioxidant activity were check and compared.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fatigue | Drug: KRG (Korea Red ginseng) Drug: Placebo (for KRG) | Phase 4 |
Fatigue Severity Scale
We used to be KRUPP's fatigue severity scale. The survey has nine questions as following: (1) my motivation is lower, when I am fatigued (2) exercise brings on my fatigue (3) I am easily fatigued (4) fatigue interferes with my physical functioning (5) fatigue causes frequent problems for me (6) my fatigue prevents sustained physical functioning (7) fatigue interferes with carrying out certain duties and responsibilities (8) fatigue is among my 3 most disabling symptoms (9) fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree). All fatigue severity scale calculated and collected by one research nurse (C.W.K) in the Department of Internal Medicine.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 75 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis |
| Study Start Date : | August 2011 |
| Actual Primary Completion Date : | April 2012 |
| Actual Study Completion Date : | April 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Korea Red Ginseng (KRG)
KRG capsule (3,000 mg/day) for 3 weeks
|
Drug: KRG (Korea Red ginseng)
3 weeks of KRG capsule (3,000 mg/day)
Other Name: Korea Red ginseng capsule (3,000 mg/day) |
|
Placebo Comparator: Placebo (for KRG)
placebo (for KRG) for 3 weeks
|
Drug: Placebo (for KRG)
Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
Other Name: Placebo |
- Liver Enzymes [ Time Frame: 3 weeks of KRG ]aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase
- Fatigue as Measured by KRUPP's Fatigue Severity Scale [ Time Frame: 3 weeks of KRG ]
KRUPP's fatigue severity scale.
The survey has nine questions as following:
- my motivation is lower, when I am fatigued
- exercise brings on my fatigue
- I am easily fatigued
- fatigue interferes with my physical functioning
- fatigue causes frequent problems for me
- my fatigue prevents sustained physical functioning
- fatigue interferes with carrying out certain duties and responsibilities
- fatigue is among my 3 most disabling symptoms
- fatigue interferes with my work, family, or social life. All subjects scored each question on a 7-point scale (1 = strongly disagree to 4 = neither disagree nor agree to 7 = strongly agree).
Scores range from 9 to 63, with higher scores indicating higher fatigue
- Pro-inflammatory Cytokine [ Time Frame: 3 weeks of KRG ]tumor necrosis factor-alpha, interleukin-6
- Adiponectin [ Time Frame: 3 weeks of KRG ]enzyme-linked immunosorbent assay
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aspartate aminotransferase (AST) ≥ 50 U/L or alanine aminotransferase (ALT) ≥ 50 U/L, and Fatty liver or Hepatitis
Exclusion Criteria:
- viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, pancreatitis, hemochromatosis, Wilson's disease, drug induced liver injury, or cancer
| Responsible Party: | Ki Tae Suk, doctor, assistant professor, Chuncheon Sacred Heart Hospital |
| ClinicalTrials.gov Identifier: | NCT02331589 |
| Other Study ID Numbers: |
AFEKRG |
| First Posted: | January 6, 2015 Key Record Dates |
| Results First Posted: | February 10, 2015 |
| Last Update Posted: | February 10, 2015 |
| Last Verified: | December 2014 |
|
Fatigue Panax ginseng Chronic hepatitis Non-alcoholic Fatty Liver Disease Adiponectin |
|
Hepatitis Fatigue Liver Diseases Digestive System Diseases |

